![]() |
|
|
Vol. 27, Issue 4, 449-455, April 1999
Centre de recherche (S.J.P., C.D., M.C.B., J.P.V., M.G.B.), Despite its hepatotoxic potential, cyclosporine A (CsA) has been
reported to positively influence compensatory liver growth. To probe
the physiological consequences of CsA on the recovery of liver
function, studies were initiated in the 2/3 partially hepatectomized
(PHx) rat, taking the recovery of cytochromes P-450-dependent drug
metabolism as primary outcome. CsA was administered at a dose of 3.33 mg/kg/day for 10 days. Drug metabolism was evaluated by the recovery of
14CO2 after administration of isotopically
labeled model drugs and by studying the expression of the P-450
transcripts involved in their biotransformation before and 24 to
96 h after PHx. Before PHx, neither the steady-state mRNA nor the
in vivo disposition of caffeine (CYP1A2), erythromycin (CYP3A2 and
3A1), or aminopyrine (CYP2B1 and 2C11) were influenced by CsA. Studies
24 h after PHx revealed a 29 to 39% reduction in the elimination
of [14C]aminopyrine and [14C]erythromycin,
which was unaffected by CsA. Their metabolism at 48 to 96 h after
PHx also remained unaffected by CsA. By contrast, postPHx,
[14C]caffeine elimination decreased to a level closely
proportional to the loss in liver mass. In addition, CsA accelerated
the recovery and/or prevented the decrease of caffeine elimination
24 h after PHx but not at later time points, indicating an early,
but unsustained, beneficial effect of CsA on the recovery of
CYP1A2-mediated activities. These data show that at the critical time
of greatest loss in liver mass, CsA has only a selective influence on
the biotransformation of cytochrome P-450 protein-dependent activities
and that its effect on the regeneration process does not translate into
an overall accelerated recovery of the hepatic drug-metabolizing function.
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
C. Theodoropoulos, C. Demers, J.-L. Petit, and M. Gascon-Barre High sensitivity of rat hepatic vitamin D3-25 hydroxylase CYP27A to 1,25-dihydroxyvitamin D3 administration Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E138 - E147. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Provencher and M. Gascon-Barre Effect of Cyclosporine A on Hepatic Compensatory Growth: Role of Calcium Status J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 58 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Theodoropoulos, C. Demers, A. Mirshahi, and M. Gascon-Barre 1,25-Dihydroxyvitamin D3 downregulates the rat intestinal vitamin D3-25-hydroxylase CYP27A Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E315 - E325. [Abstract] [Full Text] [PDF] |
||||